Bibliography
- GERSHENWALD JE, THOMPSON W, MANSFIELD PF et al.: Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. Clin. Oncol (1999) 17(3):976–983.
- CASCINELLI N, MORABITO A, SANTINAMI M et al: Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet (1998) 351(9105):793–796.
- BLEICHER R, ESSNER R, FOSHAG LJ et al: Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J. Clin. Oncol (2003) 21(7):1326–1331.
- REEVES ME, DELGADO R, BUSAM KJ et al: Prediction of nonsentinel lymph node status in melanoma. Ann. Surg. Omni (2003) 10(1):27–31.
- KIRKWOOD JM, MANOLA J, IBRAHIM J et al.: A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. (2004) 10(5):1670–1677.
- ••A valuable analysis of the evidence behindhigh-dose IFN-a therapy as the standard of care for high-risk (stages JIB and III) resected melanoma.
- GRADILONE A, GAZZANIGA P, RIBUFFO D et al: Survivin, bc1-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. Clin. Oncol (2003) 21(2):306–312.
- FARMER PJ, GIDANIAN S, B et al: Melanin as a target for melanoma chemotherapy: pro-oxidant effect of oxygen and metals on melanoma viability. Pigment Cell Res. (2003) 16(3):273–279.
- SCAFFIDI P, MISTELI T, AND BIANCHI ME: Release of chromatin protein HMGB1 by necrotic cells triggers. Nature (2002) 418(6894):191–195.
- POSER I, GOLOB M, BUETTNER R et al.: Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. MM. Cell. Biol. (2003) 23(8):2991–2998.
- TAGUCHI A, BLOOD DC, TORO G et al.: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (2000) 405(6784):354–360.
- KUNIYASU H, CHIHARA Y, T: Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep. (2003) 10(2):445–448.
- SHI Y, SAWADA J, SUI G et al: Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature (2003) 422(6933):735–738.
- BASTIAN BC, OLSHEN AB, LEBOIT PE et al.: Classifying melanocytic tumors based on DNA copy number changes. Am. Pathol (2003) 163(5):1765–1770.
- MALDONADO J, TIMMERMAN L, FRIDLYAND J et al.: Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway. Am.j Pathol (2004) 164:1783–1787.
- ESSNER R, KOJIMA M: Dendritic cell function in sentinel nodes. Oncology (Huntingt) (2002) 16(1 Suppl. 1):27–31.
- TERANDO A, ROESSLER B, MULE. J: Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector. Cancer Gene Ther. (2004) 11:165–173.
- ASAVAROENGCHAI W, KOTERA Y, MULE. J: Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc. Natl. Acad. Sci. USA (2002) 99:932–938.
- CHUNG M, GUPTA RK, HSUEH E et al.: Humoral immune response to a therapeutic polyvalent cancer vaccine after resection of thick primary melanoma and sentinel lymphadenectomy. Clin. Oncol (2003) 21(2):313–319.
- MIDDLETON MR, GROB JJ, AARONSON N et al.: Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Clin. Oncol (2000) 18(1):158–166.
- O'DAY SJ, BOASBERG PD, PIRO L et al: Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin. Cancer Res. (2002) 8(9):2775–2781.
- ATKINS MB, LOTZE MT, JP et al.: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.j Clin. Omni (1999) 17(7):2105–2116.
- ••Data behind the FDA approval ofhigh-dose IL-2 for metastatic melanoma.
- AGARWALA SS, GLASPY J, O'DAY SJ et al.: Results from a randomized Phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.' Clin. Oncol (2002) 20(1):125–133.
- ••Combination of histamine and low-doseIL-2 in a well-tolerated regimen revealing improved survival in patients with metastatic melanoma and liver metastases, not excluding patients with ocular primary.